Bandari Jathin
Known title: Chief Medical OfficerCIK: 0001903622
Associated companies
Transaction History
| TARA | ▼ Sell | Tax Withholding | 2,879 | $5K | 1/19/2024 | View on chart |
| TARA | ▲ Buy | Grant | 23,000 | $0 | 1/19/2024 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 1,877 | $4K | 1/10/2024 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 682 | $2K | 7/3/2023 | View on chart |
| TARA | ▲ Buy | Grant | 20,700 | $0 | 1/19/2023 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 1,876 | $6K | 1/10/2023 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 682 | $2K | 7/1/2022 | View on chart |
| TARA | ▲ Buy | Grant | 13,500 | $0 | 1/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Protara Completes THRIVE-3 Trial Enrollment
Protara Therapeutics has finished enrolling patients in the Phase 2b dose confirmation phase of its THRIVE-3 registrational trial for IV Choline Chloride. This milestone marks a significant step in the development process for the company's lead product. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding the upcoming trial results.
Protara Completes THRIVE-3 Trial Enrollment. Protara Therapeutics has finished enrolling patients in the Phase 2b dose confirmation phase of its THRIVE-3 registrational trial for IV Choline Chloride. This milestone marks a significant step in the development process for the company's lead product. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding the upcoming trial results.